Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02336165
Registration number
NCT02336165
Ethics application status
Date submitted
23/12/2014
Date registered
12/01/2015
Date last updated
12/10/2022
Titles & IDs
Public title
Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
Query!
Scientific title
Phase 2 Study to Evaluate the Clinical Efficacy and Safety of MEDI4736 in Patients With Glioblastoma (GBM)
Query!
Secondary ID [1]
0
0
LUD2013-006
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Glioblastoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Brain
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Durvalumab
Treatment: Other - Standard radiotherapy
Other interventions - Bevacizumab
Experimental: Cohort A - Subjects with newly diagnosed unmethylated MGMT GBM receive durvalumab (10 mg/kg Q2W) + standard radiotherapy.
Experimental: Cohort B - Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) as monotherapy.
Experimental: Cohort B2 - Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + bevacizumab (10 mg/kg Q2W).
Experimental: Cohort B3 - Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + bevacizumab (3 mg/kg Q2W).
Experimental: Cohort C - Bevacizumab-refractory subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + continued bevacizumab (10 mg/kg Q2W).
Treatment: Drugs: Durvalumab
Durvalumab is administered as an IV infusion over 60 ± 5 minutes Q2W.
Treatment: Other: Standard radiotherapy
Focal radiotherapy is administered at 2 Gy given daily 5 days per week for a total of 60 Gy over 30 fractions per local institutional guidelines or local prescribing information. On days when radiotherapy and durvalumab overlap, radiotherapy is administered first followed by durvalumab.
Other interventions: Bevacizumab
Bevacizumab is administered as an IV infusion (per local prescribing information) Q2W. When durvalumab and bevacizumab are administered together (i.e., Cohorts B2, B3, and C), durvalumab is administered first followed by a 1-hour observation period, after which, bevacizumab is infused.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Treatment: Other
Query!
Intervention code [3]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival Rate at 12 Months (OS-12) as Estimated Using the Kaplan-Meier Method (Cohort A)
Query!
Assessment method [1]
0
0
OS-12 with 90% confidence interval (CI) is the primary endpoint of Cohort A and is the percentage of subjects who remain alive at 12 months, where OS is measured from the time of diagnosis until the recorded date of death or last follow-up. Subjects who are lost to follow-up at the time of the analysis will be censored on the date of last follow-up.
Query!
Timepoint [1]
0
0
Up to 12 months
Query!
Primary outcome [2]
0
0
Progression-free Survival Rate at 6 Months (PFS-6) as Estimated Using the Kaplan-Meier Method (Cohorts B, B2, and B3)
Query!
Assessment method [2]
0
0
PFS-6 is the primary endpoint of Cohorts B, B2, and B3, and is the percentage of subjects who have not progressed at 6 months, with PFS measured from the date of the first dose of study treatment to the date of earliest disease progression (PD) based on modified Response Assessment in Neuro-Oncology (RANO) criteria or to the date of death, if PD does not occur. Per the RANO criteria, PD indicates any new lesion or a 25% increase in sum of the products of perpendicular diameters of enhancing lesions, or clear clinical deterioration per the Investigator (Wen et al. J Clin Oncol 2010; 28(11):1963-72).
Query!
Timepoint [2]
0
0
Up to 6 months
Query!
Primary outcome [3]
0
0
Overall Survival Rate at 6 Months (OS-6) as Estimated Using the Kaplan-Meier Method (Cohort C)
Query!
Assessment method [3]
0
0
OS-6 is the primary endpoint of Cohort C and is the percentage of subjects who remain alive at 6 months, where OS is measured from the date of the first dose of study treatment until the recorded date of death or last follow-up. Subjects who are lost to follow-up at the time of the analysis will be censored on the date of last follow-up.
Query!
Timepoint [3]
0
0
Up to 6 months
Query!
Secondary outcome [1]
0
0
Number of Participants With Treatment-emergent Adverse Events
Query!
Assessment method [1]
0
0
Toxicity is graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. Adverse events (AEs) are reported based on clinical laboratory tests, vital sign and weight measurements, physical examinations, performance status evaluations, magnetic resonance imaging, and any other medically indicated assessments, including subject interviews, from the time informed consent is signed through 90 days after the last dose of durvalumab. AEs are considered to be treatment emergent if they occur or worsen in severity after the first dose of study treatment.
Query!
Timepoint [1]
0
0
Up to 15 months
Query!
Secondary outcome [2]
0
0
Median PFS as Estimated Using the Kaplan-Meier Method
Query!
Assessment method [2]
0
0
PFS is measured from the date of the first dose of study treatment to the date of earliest PD based on modified RANO criteria or to the date of death, if PD does not occur. Per the RANO criteria, PD indicates any new lesion or a 25% increase in sum of the products of perpendicular diameters of enhancing lesions, or clear clinical deterioration per the Investigator (Wen et al. J Clin Oncol 2010; 28(11):1963-72).
Query!
Timepoint [2]
0
0
Up to 15 months
Query!
Secondary outcome [3]
0
0
Median OS as Estimated Using the Kaplan-Meier Method
Query!
Assessment method [3]
0
0
All subjects are followed for survival at least every 6 months for up to 3 years following initiation of study treatment. In Cohort A, OS is measured from the date of diagnosis until the recorded date of death or last follow-up. In Cohorts B, B2, B3, and C, OS is measured from the date of the first dose of study treatment until the recorded date of death or last follow-up. Subjects who remain alive or are lost to follow-up at the time of the analysis are censored on the date of last follow-up.
Query!
Timepoint [3]
0
0
Up to 36 months
Query!
Secondary outcome [4]
0
0
Number of Subjects With Best Overall Response
Query!
Assessment method [4]
0
0
Radiographic response is assessed by consistent imaging methods every (q) 8 to 9 weeks during study treatment administration. Response is categorized per the modified RANO criteria: complete response (CR) indicates no new lesions and disappearance of all disease sustained for = 4 weeks; partial response (PR) indicates no new lesions, no progression of non-measureable disease, and = 50% decrease from baseline in sum of products of perpendicular diameters of measurable lesions sustained for = 4 weeks; stable disease (SD) indicates non-qualification for CR, PR, or progressive disease (PD); PD indicates any new lesion or a 25% increase in sum of the products of perpendicular diameters of enhancing lesions, or clear clinical deterioration per the Investigator (Wen et al. J Clin Oncol 2010; 28(11):1963-72).
Query!
Timepoint [4]
0
0
Up to 15 months
Query!
Secondary outcome [5]
0
0
Mean Changes From Baseline in the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30)
Query!
Assessment method [5]
0
0
Health-related quality of life was measured using the validated EORTC-QLQ-C30. Questionnaires may be completed by the subject or with the assistance of the examiner at baseline prior to initiation of study therapy, and then approximately every 8 weeks while on study treatment (prior to discussing treatment response at each visit, whenever possible).
All questions are answered using a categorical scale (1 = not at all; 2 = a little; 3 = quite a bit; 4 = very much for symptoms and 1= very poor; 7= excellent for global heath questions). Scores were linearly transformed to 0 to 100 scales so that higher scores represented a higher level of functioning.
Overall scores were calculated for each patient for each timepoint (Giesinger J et al Journal of Clinical Epidemiology. 2016 Jan;69:79-88). Mean change from baseline where baseline is the last non-missing value before the administration of MEDI4736 was reported.
Query!
Timepoint [5]
0
0
Up to 12 months
Query!
Secondary outcome [6]
0
0
Mean Changes From Baseline in the EORTC Brain Cancer Quality of Life Questionnaire (EORTC-QLQ-BN-20)
Query!
Assessment method [6]
0
0
Health-related quality of life was measured using an EORTC quality of life questionnaire designed specifically for subjects with brain tumors (BN-20). Questionnaires may be completed by the subject or with the assistance of the examiner at baseline prior to initiation of study therapy, and then approximately every 8 weeks while on study treatment (prior to discussing treatment response at each visit, whenever possible). All single questions are answered using a categorical scale (e.g., 1 = not at all; 2 = a little; 3 = quite a bit; 4 = very much) and linearly transformed to 0 to 100 scales with higher scores for a symptom scale representing higher level of symptoms. The evaluation of HRQoL at each timepoint was measured by mean changes from baseline where baseline is the last non-missing value before the administration of MEDI4736 was reported.
Query!
Timepoint [6]
0
0
Up to 12 months
Query!
Eligibility
Key inclusion criteria
Inclusion Criteria [criteria apply to all cohorts unless otherwise specified]:
1. Cohort A: Subjects with newly diagnosed, untreated, unmethylated MGMT GBM who are
eligible for standard radiation therapy.
2. Cohorts B, B2, B3 and C: First or second recurrence of GBM by diagnostic biopsy or
contrast enhanced magnetic resonance imaging (MRI) per modified Response Assessment in
Neuro-oncology (RANO) criteria, with last baseline MRI confirmation within 14 days
prior to Study Day 1. Note: Recurrence is defined as progression following therapy
(i.e., chemotherapy; radiation). If the subject had a surgical resection for relapsed
disease and no anti-tumor therapy was administered for up to 12 weeks, and the subject
has further evidence of tumor growth or undergoes another resection, this will be
considered as one episode of recurrence.
3. Cohorts B, B2, B3 and C: On Study Day 1, at least 12 weeks from prior radiotherapy
(unless progressive disease outside of the radiation field or histopathologic
confirmation of unequivocal tumor).
4. Cohorts B, B2, B3: No prior vascular endothelial growth factor (VEGF)/VEGF receptor
targeted therapy; Cohort C: No more than one prior bevacizumab regimen.
5. Cohorts B, B2, B3 and C: Recovery from any prior treatment clinically significant,
related adverse events to grade = 1 or pretreatment baseline with the exception of
alopecia and laboratory values listed per inclusion criteria.
6. Subjects with measurable or non-measurable disease.
7. Histopathologic confirmation of glioblastoma.
8. At the time of Study Day 1, subjects must be at least 4 weeks since major surgical
procedure, open biopsy, or significant traumatic injury; there should be no
anticipation of need for major surgical procedure during the course of the study.
There should be no core biopsy or other minor surgical procedure, excluding placement
of a vascular access device, within 7 days prior to Study Day 1.
9. Subjects who have previously been treated with the Optune™ device are eligible for the
study as long as toxicity related to the treatment has resolved to = grade 1 or
baseline.
10. Eastern Cooperative Oncology Group (ECOG) = 1 or Karnofsky performance status of = 70.
11. Adequate hematologic, renal and hepatic function, as defined below:
- Absolute neutrophil count = 1000/mm^3;
- Platelet count = 100,000/mm^3;
- Total bilirubin = 1.5 x upper limit of normal (ULN); or if subject has Gilbert
syndrome, then total bilirubin = 3 x ULN;
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.0 x ULN;
- Creatinine = 1.5 x ULN or creatinine clearance (CrCl) = 50 mL/min (using the
Cockcroft-Gault formula):
- Female CrCl = (140 - age in years) x weight in kg x 0.85/72 x serum
creatinine in mg/dL;
- Male CrCl = (140 - age in years) x weight in kg x 1.00/72 x serum creatinine
in mg/dL;
- Cohorts B2, B3 and C: Urinary protein quantitative value of = 30 mg/dL in
urinalysis or =1+ on dipstick, unless quantitative protein is < 1000 mg in a
24-hour urine sample.
12. Age must be greater than or equal to 18 years at date of consent.
13. Written informed consent and any locally required authorization (e.g., Health
Insurance Portability and Accountability Act [HIPAA] in the United States) obtained
from the subject/legal representative prior to performing any protocol-related
procedures, including screening evaluations.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria [criteria apply to all cohorts unless otherwise specified]:
1. Primary tumors localized to the brain stem or spinal cord.
2. Locally directed therapies including but not limited to stereotactic radiosurgery,
re-irradiation, Gliadel®, and therapeutics administered by direct injection or
convection-enhanced delivery within 6 months of start of study treatment.
3. Prior exposure to durvalumab or other programmed cell death-1 (PD-1), programmed cell
death ligand-1 (PD-L1), cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)
antibodies.
4. Presence of diffuse leptomeningeal disease or extracranial disease.
5. Active, suspected or prior documented autoimmune disease (including inflammatory bowel
disease, celiac disease, irritable bowel syndrome, Wegner's granulomatosis and
Hashimoto's thyroiditis). Subjects with vitiligo, type I diabetes mellitus, residual
hypothyroidism due to autoimmune condition only requiring hormone replacement,
psoriasis not requiring systemic treatment, or conditions not expected to recur in the
absence of an external trigger are permitted to enroll.
6. Known primary immunodeficiency or active human immunodeficiency virus.
7. Known active or chronic viral hepatitis or history of any type of hepatitis within the
last 6 months indicated by positive test for hepatitis B virus surface antigen or
hepatitis C virus ribonucleic acid (hepatitis C virus antibody).
8. History of organ transplant requiring use of immunosuppressive medication.
9. History of active tuberculosis.
10. Significant active systemic illness including infections requiring intravenous
antibiotics.
11. Current pneumonitis or interstitial lung disease.
12. Other invasive malignancy within 2 years prior to entry into the study, except for
those treated with surgical therapy only.
13. History of severe allergic reactions to any unknown allergens or any components of the
study drugs.
14. Any prior grade = 3 immune-related adverse event (irAE) or any prior
corticosteroid-refractory irAE.
15. Mental impairment that may compromise the ability to give informed consent and comply
with the requirements of the study.
16. Lack of availability for follow-up assessments.
17. Lack of availability for Post Study Follow-up contacts to determine relapse and
survival.
18. Women who are breast-feeding or pregnant as evidenced by positive serum pregnancy test
(minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin).
19. Women of childbearing potential not using a medically acceptable means of
contraception for the duration of the study and unsterilized males not willing to
abide by protocol-specified requirements for contraception.
20. If a subject previously received another investigational treatment, the last dose of
investigational treatment was administered within 4 weeks of Day 1 of the study.
21. Any condition that, in the clinical judgment of the treating physician, is likely to
prevent the subject from complying with any aspect of the protocol or that may put the
subject at unacceptable risk.
22. Cohorts B2, B3, and C:
- Evidence of hemorrhage on the baseline MRI or computed tomography (CT) scan other
than those that are = grade 1 and either post-operative or stable on at least two
consecutive scans;
- Current use of warfarin sodium or any other Coumadin®-derivative anticoagulant.
Participant must be off Coumadin-derivative anticoagulants for at least 7 days
prior to starting study drug. Low molecular weight heparin and Factor Xa
antagonists are allowed;
- History of clinically significant bleeding within 6 months of enrollment;
- History of arterial thromboembolism within 12 months prior to enrollment;
- Inadequately controlled hypertension (defined as systolic blood pressure > 150
and/or diastolic blood pressure > 90 mmHg on antihypertensive medications);
- Any prior history of hypertensive crisis or hypertensive encephalopathy;
- Clinically significant cardiovascular disease within 12 months prior to
enrollment (or randomization), including myocardial infarction, unstable angina,
grade 2 or greater peripheral vascular disease, cerebrovascular accident,
transient ischemic attack, congestive heart failure, or arrhythmias not
controlled by outpatient medication, percutaneous transluminal coronary
angioplasty/stent;
- Evidence of bleeding diathesis or coagulopathy;
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to study enrollment;
- Serious, non-healing wound, ulcer, or bone fracture.
23. Subjects must not donate blood while on study and for at least 90 days following the
last durvalumab treatment.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
26/02/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
6/07/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
159
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Facility - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
- Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Maryland
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Massachusetts
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Missouri
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New York
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Ludwig Institute for Cancer Research
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
MedImmune LLC
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
Cancer Research Institute, New York City
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Other collaborator category [3]
0
0
Other
Query!
Name [3]
0
0
Cure Brain Cancer Foundation, Australia
Query!
Address [3]
0
0
Query!
Country [3]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is an ongoing Phase 2, open-label, multicenter, non-randomized study of MEDI4736
(durvalumab) in subjects with glioblastoma (GBM) enrolled into 5 non-comparative cohorts.
Primary study objectives, which vary by cohort due to differences in subject populations,
include evaluation of the clinical efficacy as measured by the overall survival (OS) rate at
12 months (Cohort A), progression-free survival (PFS) at 6 months (Cohorts B, B2, and B3),
and OS at 6 months (Cohort C). For all cohorts, secondary objectives include evaluation of
the safety/tolerability and clinical efficacy of study treatment, and exploratory objectives
include evaluation of the neurologic function and correlative biomarkers.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02336165
Query!
Trial related presentations / publications
Giesinger JM, Kieffer JM, Fayers PM, Groenvold M, Petersen MA, Scott NW, Sprangers MA, Velikova G, Aaronson NK; EORTC Quality of Life Group. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. J Clin Epidemiol. 2016 Jan;69:79-88. doi: 10.1016/j.jclinepi.2015.08.007. Epub 2015 Sep 28.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
David A. Reardon, MD
Query!
Address
0
0
Dana-Farber Cancer Institute
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02336165
Download to PDF